#USA #Stockholm #SiPore Technology #Sigird #Glucose Stabiliser

SIGRID Expands into U.S. Physician Market

In an exciting development for metabolic health care, SIGRID, a Swedish innovative consumer care company known for its remarkable Glucose Stabiliser utilizing patented SiPore® technology, announced its entry into the U.S. physician market. This expansion follows a successful pilot program conducted with select integrative and functional medicine clinics across the United States.

The Expansion Initiative

As part of its efforts to increase accessibility and usability of its product, SIGRID has entered into a collaboration with seasoned industry experts to create a dedicated sales network aimed at healthcare professionals. This strategic move is a significant step in SIGRID’s overarching goal to revolutionize metabolic health through effective, evidence-based solutions that earn the trust of both community members and health practitioners.

Sana Alajmovic, the co-founder and CEO of SIGRID, emphasized the importance of this expansion, stating, "Expanding into the physician channel is the next evolution for SIGRID. Physicians are actively seeking patented, clinically validated tools that can produce tangible results for their patients—and our SiPore® technology has emerged as a trusted solution."

Success Stories from the Pilot Program

Feedback from the pilot program participants highlights the positive impact of the Glucose Stabiliser on patient care. At bVital in Park City, Utah, Dr. Greg Eckel noted, "Integrating the Glucose Stabiliser into our precision protocols has significantly improved our patients' glucose time-in-range. This measurable progress has played a crucial role in reducing neuroinflammation and supporting the body’s healing capability."

Moreover, Barbie Schrick, the founder and Clinical Director of Full Circle Health in Edmond, Oklahoma, remarked, "The Glucose Stabiliser has transformed our patients' wellness journeys. It empowers them to effectively manage cravings, stabilize blood sugar, and enhance digestion without resorting to invasive methods."

Partnering with SIGRID

SIGRID is looking to expand its partnerships with healthcare professionals and innovators who share a commitment to providing science-backed solutions that can be proven effective for patients. For those interested in collaboration and white-label opportunities, SIGRID offers a robust framework designed specifically to support healthcare initiatives.
For more details on partnerships, potential collaborators can reach out through the direct contact established on SIGRID's platform.

Understanding Glucose Stabiliser

With over 15 years of rigorous research including six clinical trials, the Glucose Stabiliser represents a non-pharmaceutical approach to blood sugar regulation and weight management. It is designed to provide health-conscious individuals with consistent daily support in managing their blood sugar levels effectively. This dietary supplement has been crafted using cutting-edge SiPore® technology, which works by decelerating the digestion of carbohydrates and fats, thereby facilitating stable energy levels, promoting weight management while maintaining muscle mass, and enhancing overall metabolic health.

SIGRID’s commitment to advancing metabolic health reflects a progressive shift in healthcare, providing patients with tools that not only enhance their well-being but also enable healthcare professionals to deliver more effective treatment plans. As SIGRID continues to work with healthcare providers across the United States, the potential for improved patient outcomes in metabolic health is truly promising.

For more about the Glucose Stabiliser and the advancements in metabolic health, visit www.sigridstabiliser.com.